Class I - Dangerous
Lack of Processing Controls.
💊
Drugs Recalls
Prescription and over-the-counter medications
17,302 Total Recalls
Spironolactone Tablets, USP, 25 mg, 100-count bottle, Rx only, Mfg. by: Frontida BioPharm, Inc., 1100 Orthodox St, Philadelphia, PA 19124, Dist. by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, NDC 53489-143-01
SUN PHARMACEUTICAL INDUSTRIES
Class I - Dangerous
Presence of foreign substance: identified as aluminum.
Class I - Dangerous
Lack of Processing Controls.
RECOMBINATE, [Antihemophilic Factor (Recombinant)], 5 mL vials, Rx Only, Takeda Pharmaceuticals USA, Cambridge, MA 02142, NDC: 00944-2843-01
Cardinal Health
Class I - Dangerous
CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.
Class I - Dangerous
Lack of Processing Controls.
Doxepin Hydrochloride Capsules, USP, 10 mg, 100 Capsules, Rx only, Manufactured by: Alembic Pharmaceuticals Limited, Panela v 389350, Gujarat, India, Manufactured for: Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, USA, NDC 62332-637-31
Alembic Pharmaceuticals Limited
Class I - Dangerous
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
Class I - Dangerous
Lack of Processing Controls.
Xolair (omalizumab injection), 75 mg/0.5 ml, Rx only, Genentech, Inc., South San Francisco, CA 94080, NDC 50242-214-55
Cardinal Health
Class I - Dangerous
CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.
Class I - Dangerous
Lack of Processing Controls.
Class I - Dangerous
Lack of Processing Controls.
Class I - Dangerous
Lack of Processing Controls.
Class I - Dangerous
Lack of Processing Controls.
Xolair (omalizumab injection), 150 mg/ml, 1 auto-injector, Rx only, Genentech, Inc, South San Francisco, CA 9408, NDC: 50242-215-55.
Cardinal Health
Class I - Dangerous
CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.
Class I - Dangerous
Lack of Processing Controls.
Class I - Dangerous
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
Class I - Dangerous
Labeling: Incorrect or Missing Lot and/or Exp Date: released with wrong expiry date as Feb.2027 instead of Jan.2027
Class I - Dangerous
Defective Container: spike of the cap becomes lodged in the nozzle of the product bottle.
Class I - Dangerous
CGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess, rendering the products adulterated.
Class I - Dangerous
CGMP Deviations; particulates identified during visual inspection
Lorazepam Injection, USP, 2 mg/mL, 25 x 1mL vials/carton, Rx Only, Manufactured by: Hikma Berkeley Heights, NJ 07922, NDC# 0641-6044-25
Hikma Pharmaceuticals USA
Class I - Dangerous
Failed Impurities/Degradation Specifications: An out-of-Specification for total related compounds